Switch theme
Sign up to access all valuation multiples
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
2007
81
LTM Revenue $11.2M
Last FY EBITDA -$71.7M
$153M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tonix Pharmaceuticals has a last 12-month revenue (LTM) of $11.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Tonix Pharmaceuticals achieved revenue of $10.1M and an EBITDA of -$71.7M.
Tonix Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tonix Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.2M | XXX | $10.1M | XXX | XXX | XXX |
| Gross Profit | $4.5M | XXX | $2.3M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 23% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$71.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -711% | XXX | XXX | XXX |
| EBIT | -$104M | XXX | -$75.2M | XXX | XXX | XXX |
| EBIT Margin | -926% | XXX | -745% | XXX | XXX | XXX |
| Net Profit | -$113M | XXX | -$130M | XXX | XXX | XXX |
| Net Margin | -1009% | XXX | -1288% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Tonix Pharmaceuticals's stock price is $39.
Tonix Pharmaceuticals has current market cap of $284M, and EV of $153M.
See Tonix Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $153M | $284M | XXX | XXX | XXX | XXX | $-81.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Tonix Pharmaceuticals has market cap of $284M and EV of $153M.
Tonix Pharmaceuticals's trades at 15.2x EV/Revenue multiple, and -2.1x EV/EBITDA.
Equity research analysts estimate Tonix Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tonix Pharmaceuticals has a P/E ratio of -2.5x.
See valuation multiples for Tonix Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $284M | XXX | $284M | XXX | XXX | XXX |
| EV (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV/Revenue | 13.7x | XXX | 15.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.1x | XXX | XXX | XXX |
| EV/EBIT | -1.5x | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | 34.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.5x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTonix Pharmaceuticals's last 12 month revenue growth is 369%
Tonix Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Tonix Pharmaceuticals's rule of 40 is -1100% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tonix Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tonix Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 369% | XXX | 184% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -711% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1100% | XXX | -342% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 396% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 768% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tonix Pharmaceuticals acquired XXX companies to date.
Last acquisition by Tonix Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Tonix Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tonix Pharmaceuticals founded? | Tonix Pharmaceuticals was founded in 2007. |
| Where is Tonix Pharmaceuticals headquartered? | Tonix Pharmaceuticals is headquartered in United States of America. |
| How many employees does Tonix Pharmaceuticals have? | As of today, Tonix Pharmaceuticals has 81 employees. |
| Who is the CEO of Tonix Pharmaceuticals? | Tonix Pharmaceuticals's CEO is Dr. Seth Lederman, M.D.. |
| Is Tonix Pharmaceuticals publicy listed? | Yes, Tonix Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Tonix Pharmaceuticals? | Tonix Pharmaceuticals trades under TNXP ticker. |
| When did Tonix Pharmaceuticals go public? | Tonix Pharmaceuticals went public in 2009. |
| Who are competitors of Tonix Pharmaceuticals? | Similar companies to Tonix Pharmaceuticals include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Tonix Pharmaceuticals? | Tonix Pharmaceuticals's current market cap is $284M |
| What is the current revenue of Tonix Pharmaceuticals? | Tonix Pharmaceuticals's last 12 months revenue is $11.2M. |
| What is the current revenue growth of Tonix Pharmaceuticals? | Tonix Pharmaceuticals revenue growth (NTM/LTM) is 369%. |
| What is the current EV/Revenue multiple of Tonix Pharmaceuticals? | Current revenue multiple of Tonix Pharmaceuticals is 13.7x. |
| Is Tonix Pharmaceuticals profitable? | Yes, Tonix Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
